Alabama Opens Its First Medical Cannabis Dispensary After Five Years of Delays

On the morning of June 3, 2026, Amanda Taylor drove two hours from Cullman to a nondescript storefront off Atlanta Highway in Montgomery. She walked in, presented her medical cannabis card, and purchased a tincture bottle and a pack of gel cubes. It was the first state-sanctioned medical marijuana purchase in Alabama history.

The dispensary was Callie's Apothecary, and the transaction was nearly five years in the making — a timeline shaped by legislative battles, licensing lawsuits, court injunctions, and the kind of bureaucratic friction that has become a defining feature of cannabis reform in the Deep South.

The Legislative Foundation

Alabama's medical cannabis program traces its origins to the Darren Wesley 'Ato' Hall Compassion Act, signed into law by Governor Kay Ivey on May 17, 2021. Named after a veteran who used cannabis to manage chronic pain, the act authorized a medical cannabis program for patients with qualifying conditions including chronic pain, cancer, epilepsy, PTSD, Crohn's disease, and several other diagnoses.

The law was notable for what it excluded as much as what it allowed. Smokable flower was banned entirely — patients can only access processed products such as tablets, capsules, tinctures, gel cubes (similar to gummies), suppositories, transdermal patches, and nebulizers. The program was designed from the outset to look and feel more like a pharmacy than a dispensary, reflecting the conservative political environment in which it was crafted.

The Alabama Medical Cannabis Commission (AMCC) was established to oversee licensing, regulation, and enforcement. What followed was a licensing process that became one of the most contentious in the history of state cannabis programs.

The Licensing Saga

The AMCC's first attempt to award licenses in 2022 was met with immediate legal challenges. Applicants who were denied licenses filed lawsuits alleging scoring irregularities, conflicts of interest, and procedural violations. Courts issued injunctions. The commission voided its initial awards and started over.

A second licensing round in 2023 produced similar results — more lawsuits, more injunctions, more delays. At various points, the entire program appeared to be in jeopardy, with some legislators calling for the commission to be dissolved and the program restructured from scratch.

It was not until late 2025 that the legal landscape cleared sufficiently for licenses to be issued and facilities to begin the lengthy process of buildout, inspection, and approval. Even then, the AMCC's strict facility requirements — including seed-to-sale tracking, security specifications, and laboratory testing protocols — added months to the timeline.

Inside Callie's Apothecary

Callie's Apothecary is operated by Vince Schilleci and designed to project a clinical, professional atmosphere. The dispensary resembles a high-end pharmacy more than the cannabis retail environments found in states like Colorado or California. Display cases showcase products with medical labeling, and staff members — called patient care specialists rather than budtenders — are trained to discuss dosing, drug interactions, and condition-specific product selection.

The initial product lineup focuses on processed forms: tinctures in various THC:CBD ratios, gel cubes with precise dosing, tablets, and transdermal patches. Because Alabama prohibits smokable products, the entire inventory consists of manufactured goods that must pass through state-certified testing laboratories before reaching shelves.

Schilleci indicated that the dispensary expected to serve approximately 250 patients in its first week of operation. Early reports suggest demand exceeded projections, with patients traveling from across the state to access products.

The Patient Experience

Accessing Alabama's medical cannabis program requires several steps that can feel burdensome, particularly compared to more established programs. Patients must first obtain a diagnosis of a qualifying condition from a physician registered with the AMCC. The physician then issues a recommendation — not a prescription, as marijuana remains federally controlled — which the patient uses to apply for a medical cannabis card through the commission.

The card application involves a background check and a fee. Once approved, patients can purchase up to a 70-day supply from any licensed dispensary in the state. Product costs are not covered by insurance, and prices in the early days of the program reflect the limited supply and high compliance costs — patients should expect to pay a premium compared to markets with more competition and scale.

What's Coming Next

Callie's Apothecary is not expected to remain the only option for long. Several other dispensaries have received licenses and are in various stages of preparation, with multiple facilities expected to open across the state before the end of summer 2026. The AMCC has authorized dispensaries in several regions to ensure geographic access, though the total number of licensed retail locations will remain small compared to states with more permissive programs.

Cultivation facilities are also ramping up. The vertical integration model that Alabama adopted — where cultivators, processors, and dispensaries operate as separate licensed entities — means the supply chain must mature in lockstep. Early product selection will be limited, but operators expect to expand their menus significantly as more cultivation capacity comes online.

Alabama in Context

Alabama is now the 40th state to implement some form of legal cannabis access, joining a Southern tier that includes Mississippi, Louisiana, Arkansas, and Florida. The Deep South has been among the slowest regions to embrace cannabis reform, but the trend line is unmistakable — even in states where political leadership skews conservative, patient demand and public opinion have pushed legislatures to act.

Alabama's program is among the most restrictive in the nation. The ban on smokable flower, the limited number of licenses, and the strict regulatory framework mean that the state's medical cannabis market will develop slowly and at a smaller scale than programs in the Northeast or West Coast. But for patients like Amanda Taylor, who drove two hours for a tincture bottle, the restrictions matter less than the access.

The Bigger Picture

Alabama's dispensary opening comes at a pivotal moment for cannabis at the federal level. The DEA's rescheduling hearing, set to begin June 29, could further legitimize medical cannabis programs like Alabama's by aligning federal and state recognition of marijuana's therapeutic value. For a program that has spent five years fighting for its right to exist, federal rescheduling would provide both practical benefits — easier banking, potential insurance coverage pathways, expanded research — and symbolic validation.

The first legal medical cannabis sale in Alabama may have been a quiet transaction in a small dispensary on a Monday morning, but it represents the culmination of years of advocacy, litigation, and political negotiation. For Alabama's patients, the wait is finally over.